|
Anzemet
Anzemet
information and resources from the National Cancer Institute
Anzemet
(Other name for: dolasetron mesylate)APC8015 vaccine
A cell-based vaccine composed of autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have been exposed to a recombinant protein consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) fused to prostatic-acid phosphatase (PAP), a protein expressed by prostate cancer cells. Upon administration, the vaccine may stimulate an antitumor T-cell response against tumor cells expressing PAP. Anzemet
(Other name for: dolasetron mesylate)
|
|
|
|
|
|
KU hopes hire helps gain cancer center designation Mar 3, 2006
Bizjournals.com, ...in 1986 and helped the company and five successor companies develop drugs, including blockbusters Cardizem, Carafet, Anzemet and Allegra. ...
Anzemet
-->
|
